ATE370967T1 - Polyspezifische bindemoleküle und deren verwendung - Google Patents

Polyspezifische bindemoleküle und deren verwendung

Info

Publication number
ATE370967T1
ATE370967T1 AT99970601T AT99970601T ATE370967T1 AT E370967 T1 ATE370967 T1 AT E370967T1 AT 99970601 T AT99970601 T AT 99970601T AT 99970601 T AT99970601 T AT 99970601T AT E370967 T1 ATE370967 T1 AT E370967T1
Authority
AT
Austria
Prior art keywords
binding molecules
polyspecific binding
chain
molecules
polyspecific
Prior art date
Application number
AT99970601T
Other languages
English (en)
Inventor
Jon Weidanz
Kimberlyn Card
Linda Sherman
Norman Klinman
Hing Wong
Original Assignee
Altor Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp filed Critical Altor Bioscience Corp
Application granted granted Critical
Publication of ATE370967T1 publication Critical patent/ATE370967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99970601T 1998-10-21 1999-10-21 Polyspezifische bindemoleküle und deren verwendung ATE370967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10516498P 1998-10-21 1998-10-21

Publications (1)

Publication Number Publication Date
ATE370967T1 true ATE370967T1 (de) 2007-09-15

Family

ID=22304401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970601T ATE370967T1 (de) 1998-10-21 1999-10-21 Polyspezifische bindemoleküle und deren verwendung

Country Status (9)

Country Link
US (3) US6534633B1 (de)
EP (1) EP1124568B1 (de)
JP (1) JP4467188B2 (de)
AT (1) ATE370967T1 (de)
AU (1) AU1218000A (de)
DE (1) DE69936927T2 (de)
DK (1) DK1124568T3 (de)
ES (1) ES2293748T3 (de)
WO (1) WO2000023087A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289564B1 (de) * 2000-06-05 2018-07-18 Altor BioScience Corporation T-zell-rezeptor fusionen und konjugate und verfahren zu deren verwendung
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
WO2004050705A2 (en) * 2002-12-03 2004-06-17 Avidex Ltd. Complexes of receptors
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
AU2004289316B2 (en) * 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
US7964380B2 (en) * 2005-01-21 2011-06-21 Argylia Technologies Nanoparticles for manipulation of biopolymers and methods of thereof
GB0507046D0 (en) * 2005-04-06 2005-05-11 Celltech R&D Ltd Primers
EP1945771A1 (de) * 2005-10-28 2008-07-23 Novo Nordisk A/S Effektorlymphozyten und zielzellen bindende fusionsproteine
EP1982176A1 (de) * 2006-01-30 2008-10-22 Dako Denmark A/S Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
FR2902799B1 (fr) * 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008003100A2 (en) * 2006-06-29 2008-01-03 Xiaolian Gao Make and use of surface molecules of varied densities
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US20110070191A1 (en) * 2008-03-19 2011-03-24 Wong Hing C T cell receptor fusions and conjugates and methods of use there of
WO2009151514A1 (en) * 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2303230A2 (de) * 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Verfahren und zusammensetzungen zur verstärkten freisetzung von makromolekülen
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010074953A1 (en) * 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
EP2258719A1 (de) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
KR20130041843A (ko) * 2010-06-08 2013-04-25 이엠디 밀리포어 코포레이션 바이오 분자의 정제에 사용되는 중합체의 잔량을 검출하는 방법
AU2012316859A1 (en) 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
DK2764093T3 (en) 2011-10-05 2018-07-30 Univ Rockefeller DIMER BACTERYPHAGE LYSINES
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
WO2014014796A1 (en) * 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
PT3071593T (pt) 2013-11-22 2019-06-27 The Board Of Trustees Of The Univ Of Illionis Recetores das células t de humanos manipulados de alta-afinidade
WO2015153969A1 (en) * 2014-04-04 2015-10-08 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for t cell receptors
RU2016151645A (ru) 2014-07-01 2018-08-03 Пфайзер Инк. Биспецифические гетеродимерные диантитела и их применение
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
PL3464380T3 (pl) 2016-06-02 2025-03-31 Immunocore Limited Schemat dawkowania białka fuzyjnego specyficznego dla gp100 tcr - scfv anty-cd3
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP4491234A3 (de) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multispezifische bindungsproteine zur aktivierung natürlicher killerzellen und deren therapeutische verwendungen zur behandlung von krebs
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018166589A1 (en) * 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
CN120137046A (zh) 2018-02-08 2025-06-13 蜻蜓疗法股份有限公司 靶向nkg2d受体的抗体可变结构域
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AR114544A1 (es) 2018-08-08 2020-09-16 Dragonfly Therapeutics Inc Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
EP3833385A4 (de) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. Proteine, die nkg2d, cd16 und ein tumor-assoziiertes antigen binden
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
EP3941938A1 (de) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
WO2021158523A1 (en) 2020-02-04 2021-08-12 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
AU2024205968A1 (en) * 2023-01-05 2025-08-07 Angeles Therapeutics, Inc. Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors
GB202320012D0 (en) * 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US20260015401A1 (en) * 2024-07-10 2026-01-15 Angeles Therapeutics, Inc. Compositions and methods comprising epitopes and polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE148499T1 (de) 1990-08-09 1997-02-15 Nat Jewish Ct Immun & Respirat Herstellung monoklonaler antikörper gegen menschliches vbeta t-zellrezeptorelement unter verwendung rekombinanter dna-vektoren
EP0517895B1 (de) * 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6399368B1 (en) * 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
EP0640094A1 (de) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Rekombinantherstellung von immunoglobuun-änliche domänen in prokaryotischen zellen
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
CA2250166A1 (en) * 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
KR100712256B1 (ko) * 1997-10-02 2007-04-27 알토 바이오사이언스 코포레이션 가용성 단일쇄 ｔ-세포 수용체 단백질

Also Published As

Publication number Publication date
DE69936927D1 (de) 2007-10-04
WO2000023087A1 (en) 2000-04-27
US8105830B2 (en) 2012-01-31
EP1124568A1 (de) 2001-08-22
ES2293748T3 (es) 2008-03-16
JP2004537952A (ja) 2004-12-24
EP1124568B1 (de) 2007-08-22
DK1124568T3 (da) 2008-01-02
AU1218000A (en) 2000-05-08
JP4467188B2 (ja) 2010-05-26
EP1124568A4 (de) 2003-08-27
US20030171552A1 (en) 2003-09-11
US20120230995A1 (en) 2012-09-13
US6534633B1 (en) 2003-03-18
DE69936927T2 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
ATE276275T1 (de) Mhc-komplexe und ihre verwendungen
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
BR0209933A (pt) Uso de um ativador da transmembrana e modulador de cálcio, e proteìna de fusão de (taci) - imunoglobulina interatuadora do ligando da ciclofilina, proteìna de fusão, molécula de ácido nucleico, e, composição farmacêutica
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
DE69942981D1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
DE69738454D1 (de) Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
AR029642A1 (es) Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
EP1071443A4 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
NO20022441L (no) Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse
DK1121594T3 (da) Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
EA200400384A1 (ru) Растворимый рецептор т-клетки
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper
CY1116268T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0772ρ και μεθοδοι χρησεις αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1124568

Country of ref document: EP